Featured Research Search Results
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Observing People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
Clinicaltrials.gov identifier:
NCT01443468
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
Clinicaltrials.gov identifier:
NCT02693535
Treatment
Cancer treatment study for people with advanced solid tumors
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation
Clinicaltrials.gov identifier:
NCT04858334
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
Blood Markers of Early Pancreas Cancer
Clinicaltrials.gov identifier:
NCT03568630
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk
Cancer Experience Registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
Clinicaltrials.gov identifier:
NCT04150042
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Advanced solid tumors
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Pancreatic Cancer Screening Study for High Risk People
Clinicaltrials.gov identifier:
NCT03250078
Prevention
Screening study to detect pancreatic cancer and precancer
ELLIE's Project
Quality of Life
A survey for people with a hereditary cancer genetic mutation